Navigate Fool.com
Will GILD beat
the market?

Gilead Sciences


Community Rating: 4 Stars: Favorite

73.97 0.11 (0.15%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $74.93
Previous Close $73.86
Daily Range $71.63 - $75.00
52-Week Range $46.70 - $84.88
Market Cap $113.8B
P/E Ratio 26.28
Dividend (Yield) $0.00 (0.0%)
Volume 19,762,667
Average Daily Volume 20,759,266
Current FY EPS $4.40

How do you think GILD
will perform against the market?

Top GILD Bull/Bear Pitches


CarolinaMatt (< 20)
Submitted January 3, 2011

Yes I get it. This company is no longer the high-flying early-stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution. But this is no old super-slow … More

0 Replies Reply Report this Post

stockfreak1 (19.13)
Submitted July 24, 2010

With more and more HIV generics around the corner it's not surprising why the CEO is selling and selling quick. Anyone actually see the retail prices on their drugs? Good God Viread is like $12 a pill … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Celgene Beats on First-Quarter Earnings: What's Next?

Celgene narrowly beat consensus estimates on earnings this morning. Will biotechs shrug off the recent downturn?

Should You Invest in Gilead Sciences, Inc. Today?

Gilead Sciences knocked it out of the park this quarter, but is that enough of a reason for you to invest?

Why Investors Are Not Chasing Gilead Endlessly Higher

Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter

Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing Johnson & Johnson's (JNJ) Olysio.

Nasdaq 100 Movers: ISRG, GILD

Companies Betting on the Next 10 Blockbuster Drugs

Say Hello to the New Fastest Growing Drug in History!

This drug absolutely shattered Vertex Pharmaceuticals' record for bringing a new drug to market and hitting the $1 billion sales plateau, accomplishing the feat in just a quarter.

U.S. stocks fall; PMI slips in April

Stocks: Cautious start ahead of tech results

US Futures Mixed Amid Earnings Deluge; Apple, Facebook Set to Report After Close

See More GILD News...





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks